While KRAS mutation is the leading cause of low survival rates in lung cancer bone metastasis patients,effective treatments are still lacking.Here,we identified homeobox C10(HOXC10)as a lynchpin in pan-KRAS-mutant lun...While KRAS mutation is the leading cause of low survival rates in lung cancer bone metastasis patients,effective treatments are still lacking.Here,we identified homeobox C10(HOXC10)as a lynchpin in pan-KRAS-mutant lung cancer bone metastasis.展开更多
基金sponsored by National Natural Science Foundation of China (82303396,82022051,82072972 and 81672883)Science and Technology Commission of Shanghai (22YF1408400)+6 种基金Shanghai Pilot Program for Basic Research (TQ20240208)Natural Science Foundation of Chongqing (CSTB2024NSCQ-JQX0009 and CSTB2024NSCQ-MSX0594)The Postdoctoral Foundation of China (2023T160122)Anti-cancer Association in Shanghai,Joint Foundation from Fudan University Shanghai Cancer Center (YJQN202102)Science&Techenology Department of Sichuan Province (2023NSFSC0705)the Fund of major military joint research project (2019LH 02)Shanghai municipal hospital emerging frontier joint research project (SHDC12024112)。
文摘While KRAS mutation is the leading cause of low survival rates in lung cancer bone metastasis patients,effective treatments are still lacking.Here,we identified homeobox C10(HOXC10)as a lynchpin in pan-KRAS-mutant lung cancer bone metastasis.
